Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Three-Step Supplement Safety Review Model Proposed by IoM

This article was originally published in The Tan Sheet

Executive Summary

Outside review organizations could play a key role in preparing dietary supplement safety monographs as part of the Institute of Medicine's Proposed Framework for Evaluating the Safety of Dietary Supplements
Advertisement

Related Content

IoM Supplement Report Emphasizes Premarket Data, AER Requirements
IoM Supplement Monograph Framework Should Reflect “Real World” – CFSAN
Melatonin, Chromium Monograph Human Safety Data Should Be Used – CRN
IoM monographs
New Dietary Ingredient Safety Standards Should Be FDA Focus – NNFA
Supplement Trade Association Consolidation Urged By CRN’s Cordaro
IoM Supplement Safety Plan’s Reliance On AER Reviews Problematic – CRN
Chaparral AER Data Resembles Kava Reports, CRN’s Cardellina Says
IoM chaparral monograph
IoM Supplement Framework Should Reflect “Relative” Safety – CHPA

Topics

Advertisement
UsernamePublicRestriction

Register

PS094343

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel